Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 6Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Prostatic Neoplasms 33Breast Neoplasms 23Stomach Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Esophageal Neoplasms 13Neoplasm Metastasis 11Sarcoma 9Neoplasms 9Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Salivary Gland Neoplasms 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Gemcitabine 8pembrolizumab 5Paclitaxel 4Capecitabine 4Albumin-Bound Paclitaxel 4Nivolumab 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3sargramostim 2poly ICLC 2fludarabine 2Prednisone 2Oxaliplatin 2Irinotecan 2Hydroxychloroquine 2Erlotinib Hydrochloride 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2temsirolimus 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1rucaparib 1resiquimod 1repotrectinib 1regorafenib 1pralsetinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma × Docetaxel × Clear all
NCT01217060 2021-04-13

Trimodality Management of T1b Esophageal Cancers

M.D. Anderson Cancer Center

Phase 1/2 Completed
4 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡